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OBJECTIVES: Clinically, patients with chronic heart failure arising from different etiologies receive the same
treatment. However, the prognoses of these patients differ. The purpose of this study was to elucidate whether
the pathogenesis of heart failure arising from different etiologies differs.
METHODS: Heart failure-related dataset GSE1145 was obtained from the Gene Expression Omnibus database.
Differentially expressed genes were identified using R. A protein-protein interaction network of the differen-
tially expressed genes was constructed using Search Tool for the Retrieval of Interacting Genes. The modules in
each network were analyzed by Molecular Complex Detection of Cytoscape. The Database for Annotation,
Visualization and Integrated Discovery was used to obtain the functions of the modules.
RESULTS: Samples contained in GSE1145 were myocardial tissues from patients with dilated cardiomyopathy,
familial cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, and post-partum cardiomyopathy.
The differentially expressed genes, modules, and functions of the modules associated with different etiologies
varied. Abnormal formation of extracellular matrix was overlapping among five etiologies. The change in cyto-
skeleton organization was specifically detected in dilated cardiomyopathy. The activation of the Wnt receptor
signaling pathway was limited to hypertrophic cardiomyopathy. The change in nucleosome and chromatin
assembly was associated with only familial cardiomyopathy. Germ cell migration and disrupted cellular calcium
ion homeostasis were solely detected in ischemic cardiomyopathy. The change in the metabolic process of
glucose and triglyceride was detected in only post-partum cardiomyopathy.
CONCLUSION: These results indicate that the pathogenesis of heart failure arising from different etiologies
varies, which may provide molecular evidence supporting etiology-based treatment for heart failure patients.
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’ INTRODUCTION
Heart failure is the end stage of various heart diseases,
including dilated cardiomyopathy, hypertension, hypertro-
phic cardiomyopathy, and myocardial infarction. Patients with
heart failure suffer from a high mortality and a poor prog-
nosis. Worldwide, the mortality of patients within 5 years
of chronic heart failure is greater than 50% (1,2). Recently,
the incidence of heart failure has been increasing due to
improvement in the treatment of underlying diseases, changes
of life style, and the aging of the population (3-5). Thus, heart
failure is a very serious global public health problem in
the 21st century, and there is an urgent need to improve the
outcome of such patients (6,7).
Currently, patients with chronic heart failure arising from
different etiologies are given the same treatment in clinical
practice, and the differences in etiology are ignored (6,7).
Although the clinical presentation of heart failure has a sim-
ilar appearance among such cases, the prognoses are different,
suggesting that the pathogeneses of heart failure arising from
different etiologies are different. This implies that the etio-
logies should be taken into consideration when deciding on
treatment options, and etiology-based treatments should be
given to patients with heart failure.
The purpose of this study was thus to elucidate whether
the pathogeneses of various types of heart failure arising from
different etiologies is different. The pathogenesis of diseases
is usually not determined by a single gene but by the inter-
actions among multiple genes forming a pathogenetic net-
work, which is characterized by determining changes in theDOI: 10.6061/clinics/2017(10)03
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gene expression profile (8-11). In a pathogenetic network,
some gene products have similar or the same functions. They
are, thus, located in the same functional unit of the network,
called a module, and work together to carry out their biolog-
ical functions (12). A microarray globally detects the expres-
sion profile of the genome and is helpful for uncovering the
pathogenesis of diseases. In this study, microarray data from
the myocardial tissues of patients with heart failure arising
from different etiologies were thus compared with those
from normal controls to identify the differentially expressed
genes (DEGs). Then, we constructed a protein-protein inter-
action (PPI) network of the DEGs and analyzed the modules
of each PPI network. Finally, we explored the functions of
these modules.
’ MATERIALS AND METHODS
Microarray data
GSE1145 was downloaded from the Gene Expression
Omnibus (GEO) database. The samples contained in GSE1145
were myocardial tissues from patients with heart failure
arising from five different etiologies, including 12 samples
arising from dilated cardiomyopathy (DCM), 5 from familial
cardiomyopathy (FCM), 5 from hypertrophic cardiomyo-
pathy (HCM), 20 from ischemic cardiomyopathy (ISCM),
and 4 from post-partum cardiomyopathy (PPCM), as well as
11 normal controls. The myocardial samples of heart failure
were collected from patients undergoing cardiac trans-
plantation whose failure arose from the different etiologies
mentioned above. The normal control myocardial samples
were collected from normal organ donors whose hearts
could not be used for transplants. The platform used was
GPL570 [HG-U133_Plus_2] Affymetrix Human Genome
U133 Plus 2.0 Array, which contains a total of 54,675 probes.
These probes correspond to 20,283 genes. When multiple
probes corresponded to one gene, the variance of the expres-
sion levels of the probes was averaged as the expression
value of the gene.
Data preprocessing
The raw data from the original CEL files were prepro-
cessed and transformed into expression values by Affy,
an R package. Then, the expression values were normalized
using the robust multiarray averaging (RMA) algorithm, and
the missing data were filled in using the k-Nearest Neighbor
(KNN) algorithm (13,14). Box plots were drawn before and
after the normalization to estimate the degree of normal-
ization (15,16).
Analysis of DEGs
Limma, a package of R, was applied to identify the DEGs
between each etiology and the normal controls (10). The
statistical method that we used was the empirical Bayes
method, which was implemented in limma (17). The thresh-
old for the DEGs was set as an adjusted p-value o0.05, and
the fold change values X2 (16).
Construction of the PPI network
Search Tool for the Retrieval of Interacting Genes
(STRING, http://string-db.org/), a database containing both
direct (physical) and indirect (functional) associations of
protein interactions, was used to predict the interactions
between the identified DEGs and to construct the protein-
protein interaction (PPI) network (18).
Analysis of the modules in the PPI network
Modules are functional units of a network. Genes with a
similar or the same function make up a certain module. Here,
Cytoscape was used to visualize the PPI network and the
molecular complex detection (MCODE), a plugin of Cytos-
cape, was used to identify the modules in each network. The
parameters of MCODE were as follows: the degrees of each
node in a module were no less than 2, and subgraphs of each
node were greater than 2 (12).
Enrichment analysis of the function of modules
The Database for Annotation, Visualization and Integrated
Discovery (DAVID, https://david.ncifcrf.gov/) was applied
to perform the functional enrichment analysis for the modules
associated with the different etiologies (19). Po0.05 was set
as the cut-off.
’ RESULTS
Data preprocessing and screening of the DEGs
After normalization, the median gene expression value
in each box was approximately at the same level, which
indicated an excellent degree of normalization (Figure 1).
Compared with the normal controls, the numbers of DEGs in
DCM, HCM, FCM, ISCM, and PPCM were different, namely,
331 (320 upregulated, 11 downregulated), 298 (198 upregulated,
100 downregulated), 685 (667 upregulated, 18 downregu-
lated), 747 (731 upregulated, 16 downregulated), and 343
(306 upregulated, 37 downregulated), respectively (Table 1).
The numbers of genes overlapping among the different
etiologies are shown in Figure 2.
PPI network construction
Based on the DEGs screened previously, a PPI network
of each etiology was constructed. The number of pairs
of genes included in the PPI networks of DCM, HCM,
FCM, ISCM, and PPCM were 128, 153, 507, 719, and 160,
respectively. Figure 3 shows the PPI network visualized by
Cytoscape.
Analysis of the modules in the PPI network
The number of modules in the PPI networks of DCM,
HCM, FCM, ISCM, and PPCM was also different, namely, 7,
7, 9, 12, and 6, respectively (Figure 4). We analyzed the over-
lapping and unique module-related genes of the different
etiologies and found that FMOD, LUM, OMD, and OGN
were overlapping genes among the five etiologies, and they
formed a module with overlap for all of the five etiologies.
The numbers of unique module-related DEGs of DCM,
HCM, FCM, ISCM, and PPCM were 8, 13, 29, 41, and 11,
respectively, which was almost half of the total module-
related DEGs (Table 2).
Functional annotation of the modules
The functions of the modules in each PPI network were
annotated using DAVID (Table 3). We found that the func-
tions of the modules in each etiology were not exactly the
same. The modules not only shared similarities but also
exhibited differences. The modules related to immune/
inflammatory response and the formation of the extracellular
matrix were overlapping in the five etiologies. The genes in
the modules related to immune response and inflammatory
response were not equal among the different etiologies.
However, FMOD, LUM, OMD, and OGN, which participate
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in the formation of the extracellular matrix, overlapped
among the five etiologies. The modules related to cytoske-
leton organization were detected specifically in heart failure
arising from DCM, with increased KIF18A and TUBE1. The
modules related to the Wnt receptor signaling pathway were
limited to heart failure arising from HCM, with increased
WIF1 and FRZB. The modules related to nucleosome and
chromatin assembly were associated only with heart failure
arising from FCM, with increased HIST1H2BN, CENPA,
HIST1H1A and HIST1H2AK. The modules related to germ
cell migration and disrupted cellular calcium ion home-
ostasis were solely detected in heart failure arising from
ISCM, with increased CXCR4, CCL5, and CXCL12. The
modules related to the metabolic process of glucose and
triglycerides were detected only in heart failure arising from
PPCM, with upregulated G6PC, GPAM, and PCK1. The
genes in the modules related to the functions mentioned
above are shown in Table 3.
’ DISCUSSION
The immune response and inflammatory response play
important roles in heart failure, leading to the development
of this disease. Circulating inflammatory cytokines are
elevated in heart failure and are used as predictors of clinical
outcome (20-22). In our research, the immune/inflammatory
response participated in heart failure arising from all five
etiologies. Although the immune/inflammatory response
was associated with heart failure induced by all five etiolo-
gies, the genes related to the immune/inflammatory response
in the different etiologies were not exactly the same, which
further indicates the differences in the pathogenesis in heart
failure arising from these different etiologies. In addition to
the immune/inflammatory response, our data showed that
the formation of extracellular matrix overlapped among the
types of heart failure arising from the five etiologies, and
the genes related to this were the same. Cardiac remodeling
is a key feature of heart failure, characterized by reduced
myocytes and increased extracellular matrix, which finally
Figure 1 - Box plots for the expression value data before and after normalization. The horizontal axis indicates the different samples,
and the vertical axis represents the expression values of the genes. The black line in each box is the median of the expression value.
Before normalization, the median gene expression value in each box was not at the same level. After normalization, the median of the
expression value was almost on the same line, suggesting an excellent performance of the normalization.
Table 1 - The number of DEGs in the different etiologies.
Etiologies DEGs Upregulated Downregulated
DCM 331 320 11
HCM 298 198 100
FCM 685 667 18
ISCM 747 731 16
PPCM 343 306 37
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result in cardiac fibrosis (23,24). The FMOD gene is a member
of the family of small interstitial proteoglycans. The encoded
protein may participate in the assembly of extracellular matrix
due to interaction with type I and type II collagen fibrils (25).
LUM, OMD, and OGN all belong to the family of small
leucine-rich proteoglycans. LUM may regulate collagen fibril
organization in the murine heart by coordinating multiple
factors of collagen assembly, and OMD may reduce the
diameter and change the shape of collagen fibrils by directly
interacting with collagen (26,27). The upregulation of OGN
may protect against cardiac fibrosis by inhibiting the prolifera-
tion and migration of cardiac fibroblasts (28). According to
our results, we should take the immune/inflammatory response
and cardiac fibrosis into consideration, and administering
related treatments for patients with heart failure may be
useful. FMOD, LUM, OMD, and OGN may be potential ther-
apeutic targets. The activation of the neurohormonal and
sympathetic systems has been demonstrated in heart failure,
and blocking these pathways using angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, and
b-adrenergic blockers is useful to reduce the progression of
heart failure and improve clinical outcomes (29-31). How-
ever, no evidence of abnormal neurohormonal and sympa-
thetic systems was observed in our data. Considering that
the samples used for GSE1145 were cardiac tissue rather than
a single type of cardiac cell, we hypothesized that changes
in the neurohormonal and sympathetic systems could occur
in a certain cell type and that the expression level of related
genes may be diluted when detected in cardiac tissue that is
a mixture of multiple cardiac cell types.
About half of patients with heart failure present an
enlarged heart and reduced cardiac pump function, which
are accompanied by cytoskeletal changes. Such changes are
not only the cause but also the consequence of reduced
systolic function in patients with heart failure. The cytoske-
leton forms a complex network that extends through the
cytoplasm and connects the nucleus, the plasma membrane,
and even the extracellular matrix. The cytoskeleton partici-
pates in the dilatation and contraction of the heart (32,33).
DCM is a primary etiology of heart failure with cardiac
dilatation and decreased cardiac function (34). We found that
the changes in cytoskeleton organization were detected
specifically in heart failure arising from DCM. KIF18A
belongs to the kinesin superfamily of microtubule-associated
molecular motors and regulates microtubule dynamics (35).
TUBE1 is a member of the tubulin superfamily and plays a
central role in the organization of microtubules (36). These
results indicate that the cytoskeleton may play an important
role in the pathogenesis of heart failure resulting from DCM.
We should, thus, focus on the changes in the cytoskeleton in
patients with heart failure arising from DCM. Administering
related treatment to these patients may reverse cytoskeletal
abnormalities and KIF18A and TUBE1 may be potential
therapeutic targets.
Wnt signaling is involved in various biological processes.
Previous studies have shown that such signaling is reacti-
vated under pathological conditions but mostly remains silent
in a normal state. Increasing evidence suggests that Wnt
signaling participates in the progression of heart failure and
is related to adverse cardiac remodeling (37,38). HCM is a
primary myocardial disease that commonly causes thicken-
ing of the myocardium (39). In our study, the activation of
the Wnt receptor signaling pathway was limited to heart
failure arising from HCM. The protein encoded by WIF1
Figure 2 - Overlapping DEGs among the groups of different etiologies. The Venn graph displays the number of differentially expressed
genes overlapping among the different etiologies. The differentially expressed genes (DEGs) shown in the figure differ significantly in
their expression value with an adjusted p-value o0.05 and a fold change 42. DCM, dilated cardiomyopathy; HCM, hypertrophic
cardiomyopathy; FCM, familial cardiomyopathy; ISCM, ischemic cardiomyopathy; PPCM, post-partum cardiomyopathy.
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functions to inhibit Wnt signaling and may impair the func-
tion and structure of the heart (40). FRZB is a type of secreted
Wnt antagonist that may inhibit fibrosis in vitro (41). This
result indicates that Wnt signaling may be extremely important
for the pathogenesis of heart failure resulting from HCM.
Wnt signaling-related treatment may have potential benefits
to patients with heart failure arising from HCM, and WIF1
and FRZB may be potential therapeutic targets.
Epigenetic regulation plays an important role in various
pathological and physiological conditions. The main mechan-
isms of epigenetic regulation include DNA methylation and
histone modifications, which influence gene expression by
affecting the assembly of the nucleosome and chromatin.
Studies have shown that epigenetic regulatory mechanisms
participate in heart failure and modulate the expression
of multiple genes that are essential for the development of
heart failure (42). FCM is a genetic disorder that is difficult
to recognize until advanced phenotypic manifestations
occur. The late phenotypes of FCM, such as an enlarged
atrium, are subtle in comparison with those of HCM and
DCM (43). Our data showed that changes in nucleosome and
chromatin assembly were associated only with heart failure
arising from FCM. HIST1H2BN and HIST1H2AK encode a
replication-dependent histone, which belongs to the histone
H2B family. They are both linked to histone H1 and par-
ticipate in the compaction of chromatin into higher order
structures in transcriptional regulation (44,45). CENPA encodes
a centromere protein that contains a histone H3-related histone
fold domain. The protein encoded by CENPA is proposed
to be a component of a modified nucleosome in which it
replaces 1 or both copies of the conventional histone H3 (46).
HIST1H1A encodes a replication-dependent histone that is
a member of the histone H1 family, which interacts with
linker DNA between nucleosomes and functions in the
compaction of chromatin into higher order structures (47).
The results suggest that epigenetic regulation is important
for heart failure arising from FCM. Epigenetic changes in
FCM, such as increased HIST1H2BN, CENPA, HIST1H1A
and HIST1H2AK, may thus be useful for distinguishing FCM
from HCM and DCM and may also be a useful therapeutic
target for patients with heart failure arising from FCM.
ISCM is caused by myocardial infarction, which eventually
develops into heart failure. It is characterized by a loss of
cardiomyocytes and the disruption of cellular calcium ion
homeostasis in the infarcted region, which leads to ventri-
cular reconstruction and cardiac dysfunction. Stem cell-based
Figure 3 - The PPI network of each etiology. The node represents the differentially expressed genes (DEGs), and the edge represents the
interaction relationship among the products of the DEGs. The modules of each network are colored yellow. DCM, dilated
cardiomyopathy; HCM, hypertrophic cardiomyopathy; FCM, familial cardiomyopathy; ISCM, ischemic cardiomyopathy; PPCM, post-
partum cardiomyopathy.
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treatments in heart failure have been tested in many trials,
and the results are promising (48). Our data showed that
germ cell migration was solely detected in heart failure aris-
ing from ISCM, suggesting that a stem cell-based treatment
may be especially beneficial for ISCM-induced heart failure.
CXCR4 encodes a CXC chemokine receptor, which has
7 transmembrane regions and is located on the cell surface.
CXCR4 can induce stem cell migration through the FAK/
PI3K/Akt and GSK3b/b-catenin pathways (49). The protein
encoded by CXCL12 functions as the ligand for the G-protein
coupled receptor and can bind to CXCR4 and regulate the
migration of stem cells (50-52). Calcium ion homeostasis is
broken in ISCM. Previous studies have indicated that Ca2+
signaling is related to the regulation of cardiac remodeling
and turnover (53). CCL5 is one of several chemokine genes
clustered on the q-arm of chromosome 17 and can activate
calcium signals through a multistep cascade (54). CXCR4
protein expression is influenced by extracellular calcium and,
thus, may enhance stem cell migration (55). CXCL12 stimu-
lates the release of intracellular calcium in a dose-dependent
manner. CXCL12-stimulated epithelial cell migration can
be abrogated by intracellular calcium chelation (56). Based
on our study, a disrupted cellular calcium ion homeostasis
was solely detected in ISCM. These results indicate that the
regulation of disrupted cellular calcium ion homeostasis may
have potential advantages for treating heart failure arising
from ISCM, and CXCR4, CCL5, and CXCL12 may be
potential therapeutic targets. However, CXCR4 and CXCL12
are also involved in germ cell migration, and further studies
are required to clarify the potential efficacy of the CXCR4 and
CXCL12 in clinical settings.
Heart failure is accompanied by energy metabolic remo-
deling, which in turn exacerbates heart failure. Free fatty
acids (FFAs) are the main substrate for the normal heart to
produce ATP. Approximately 60%-90% of ATP is derived
from the aerobic oxidation of FFAs. Upon the development
Figure 4 - Modules in the PPI network of the five different etiologies. The node represents the module-related differentially expressed
genes (DEGs), and the edge represents the interaction relationship among the products of the DEGs. DCM, dilated cardiomyopathy;
HCM, hypertrophic cardiomyopathy; FCM, familial cardiomyopathy; ISCM, ischemic cardiomyopathy; PPCM, post-partum
cardiomyopathy.
Table 2 - Overlapping and unique DEGs in the modules of the different etiologies.
Etiologies Total Genes
Overlapping 4 FMOD LUM OMD OGN
HCM (27) 13 WIF1 MSTN PRELP HLA-DPB1 MYBPC1 MYOC HTR2B THBS2 FRZB HLA-DQA1 PTGFR THBS4 COL10A1
DCM (8) 8 TNNI1 TUBE1 KCNV1 TAS2R5 KCNB1 SSTR5 KCNS1 KIF18A
FCM (55) 29 HIST1H2AK POLK CLIC2 ABCG2 CX3CR1 CD74 HIST1H2BN HLA-DRA ZEB1 HLA-DMA MSH3 GABRR3 CCL18 ALDH1A1 GPR18 RBM43
SNAI2 IL10 CCL2 HIST1H1A PROM1 PIK3CG MSH2 EPCAM SCARF1 GNG11 GP5 GABRG3 KITLG
ISCM (67) 41 SPARC FOS RGS2 RPL26 CXCR4 TTC8 HTR2A VCAM1 EIF1AY CD69 FAM134B HMGN3 NDC80 IFITM1 GADD45G FST RPS4Y1 HMGN1
PLEC HMGN2 BBS10 ARL14 SPC25 XAF1 GADD45A C11orf70 RAP1B RAB33B PRKX KIF20A GHR LIFR SESN1 RGS1 BET1 NSA2 IFNK
CCL4 CCDC111 IFI27 BBS5
PPCM (24) 11 MMRN1 IGF1 CLU PROS1 COL21A1 DKK2 KRT6A PCK1 REM2 GPAM G6PC
The numbers in parentheses indicate the total number of module-related DEGs.
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of heart failure, the substrate utilization changes. The aerobic
oxidation of FFAs diminishes, and the uptake of glucose
increases. The metabolic pattern also changes from the aerobic
oxidation of FFAs to anaerobic glycolysis (57-59). PPCM is a
secondary myocardial disease in women with left ventricular
failure and occasionally right ventricular failure. It occurs
more frequently during the last month of pregnancy or within
the first 6 months after delivery (60). Our study found that
changes in the metabolic process of glucose and triglycer-
ides were only detected in PPCM-induced heart failure,
indicating that energy metabolic remodeling may be more
important in PPCM-induced heart failure. G6PC is a multi-
subunit integral membrane protein that is composed of a
catalytic subunit and transporters for glucose. The protein
encoded by G6PC is a key enzyme in glucose homeostasis
and catalyzes the hydrolysis of D-glucose 6-phosphate to
D-glucose and orthophosphate (61). GPAM is an isoform of
glycerol-3-phosphate acyltransferase and is located on the
outer mitochondrial membrane. GAPM is required to cata-
lyze de novo synthesized fatty acids into triacylglycerol
and, thus, to divert them away from oxidation (62). PCK1
is a key player in the initial step of gluconeogenesis and
can decrease circulating free fatty acids (63). Energy meta-
bolic remodeling related molecules, such as G6PC, GPAM,
and PCK1, may emerge as potential therapeutic targets
for these patients.
The major strength of this study was that based on the
microarray dataset, we showed different pathogeneses of
heart failure arising from different etiologies and found the
similarities and differences in the DEGs among the different
types of heart failure. However, because there are only 4 or
5 samples for FCM, HCM and PPCM, our results of these
three groups may have been due to chance and must be
confirmed by increasing the sample size.
Table 3 - The annotated functions of the modules in the PPI network of each etiology.
Etiology Description p-value Gene
DCM
immune response 0.0099 RSAD2, IFI44L
inflammatory response 5.75E-4 S100A9k, SERPINA3k, LYZ
cytoskeleton-dependent intracellular transport 0.0077 MYL1, MYH6k
muscle contraction 0.0225 MYL1, MYH6k
muscle organ development 0.0310 MYL1, MYH6k
cytoskeleton organization 0.0010 CENPA, KIF18A, TUBE1
cell cycle process 0.0017 CENPA, KIF18A, TUBE1
potassium ion transport 1.39E-4 KCNS1, KCNB1, KCNV1
extracellular matrix 1.95E-5 FMOD, LUM, OMD, OGN
HCM
muscle organ development 7.19E-4 MYL1, MSTN, MYH6k
muscle contraction 3.78E-4 MYBPC1k, MYL1, MYH6k
cytoskeleton-dependent intracellular transport 0.0115 MYL1, MYH6k
Wnt receptor signaling pathway 0.0098 WIF1, FRZB
immune response 0.0026 HLA-DRB1, HLA-DPB1, HLA-DQA1
extracellular matrix 1.95E-5 FMOD, LUM, OMD, OGN
FCM
immune response 0.0258 CCL21, P2RY14, CCL5, CXCL12, HLA-DRB1, HLA-DMA, CD74, HLA-DRA
nucleosome assembly 2.31E-7 HIST1H2BN, CENPA, HIST1H1A, HIST1H2AK
chromatin assembly 2.57E-7 HIST1H2BN, CENPA, HIST1H1A, HIST1H2AK
positive regulation of protein amino acid phosphorylation 0.0196 BMP4, KITLG
inflammatory response 7.03E-4 CCL2, IL10, CCL18, F2R
negative regulation of programmed cell death 9.40E-4 PIK3CG, CCL2, IL10, F2R
JAK-STAT cascade 0.0228 CCL2, F2R
anion transport 0.0210 GABRG3, CLIC2
extracellular matrix 1.95E-5 FMOD, LUM, OMD, OGN
ISCM
immune response 1.68E-5 RGS1, CCL21, CXCR4, P2RY14, CCL5, CXCL12
cellular calcium ion homeostasis 0.0048 CXCR4, CCL5, CXCL12
germ cell migration 0.0071 CXCR4, CXCL12
patterning of blood vessels 0.0124 CXCR4, CXCL12
inflammatory response 0.0146 CCL21, CXCR4, CCL5/FOS, CCL4, F2R
ncRNA processing 0.0409 RPL26, NSA2
regulation of cell proliferation 0.0027 VCAM1, BMP4, SPARC, F2R, HTR2A
microtubule cytoskeleton organization 0.0216 SPC25, NDC80
cellular response to stress 0.0017 GADD45G, SESN1, GADD45A
regulation of cell cycle 0.0483 GADD45G, GADD45A
extracellular matrix 1.95E-5 FMOD, LUM, OMD, OGN
PPCM
response to wounding 5.98E-5 CLU, IGF1, MMRN1, PROS1
blood coagulation 0.0225 MMRN1, PROS1
anti-apoptosis 0.0450 CLU, IGF1
inflammatory response 5.75E-4 S100A9k, SERPINA3k, LYZ
triglyceride metabolic process 9.87E-6 G6PC, GPAM, PCK1
glucose metabolic process 0.0225 G6PC, PCK1
extracellular matrix 1.95E-5 FMOD, LUM, OMD, OGN
The downregulated genes are marked ‘‘k’’, and the other genes are upregulated.
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Our results indicate that the pathogenesis of heart failure
arising from different etiologies not only shares similarities
but also exhibits differences, which may provide molecular
evidence supporting the concept that etiology-based treat-
ment is required for patients with heart failure.
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